Datavault AI and Wellgistics Health Launch DelivMeds AI, a $4B Healthcare Platform

Datavault AI (NASDAQ: DVLT) has announced a binding term sheet with Wellgistics Health to create DelivMeds AI, a healthcare platform that combines AI-driven pharmacy optimization, blockchain-enabled smart contracts, biometric verification, and direct-to-consumer healthcare delivery. The initiative involves three concurrent transactions: an expanded PharmacyChain(TM) license, the acquisition of QOLPOM intellectual property, and a controlling stake in Tollo Health. The combined transactions carry an expected approximate asset value of $4 billion, subject to an independent fairness opinion, and are intended to support a national rollout of data-driven healthcare delivery and patient engagement solutions.

The partnership signifies a major step in integrating advanced technologies into healthcare. DelivMeds AI aims to leverage Datavault AI's expertise in AI-driven data experiences and monetization, combined with Wellgistics Health's pharmaceutical distribution network. The platform will utilize blockchain for smart contracts to ensure secure and transparent transactions, while biometric verification enhances patient identification and security. Direct-to-consumer delivery is expected to improve access to medications and healthcare services, particularly for individuals in underserved areas.

This announcement is important because it represents a convergence of multiple cutting-edge technologies within the healthcare sector, a trend that has been gaining momentum. The $4 billion valuation underscores the potential scale and impact of the venture. For Datavault AI, this expands its footprint beyond its core areas of acoustic sciences and data science into the healthcare vertical, potentially opening new revenue streams. For Wellgistics Health, the partnership provides access to AI and blockchain capabilities that could streamline its operations and enhance patient outcomes.

Datavault AI's technology suite includes its cloud-based platform for data valuation and monetization in the Web 3.0 environment, with divisions focused on Acoustic Sciences and Data Science. The Acoustic Sciences division features patented technologies like WiSA(R), ADIO(R), and Sumerian(R) for spatial audio. The Data Science division leverages high-performance computing for experiential data perception and secure monetization, serving industries including healthcare. The company's Information Data Exchange(R) enables Digital Twins and licensing of name, image, and likeness by anchoring to immutable metadata.

The formation of DelivMeds AI could have implications for the broader healthcare industry, as AI and blockchain are increasingly seen as solutions for reducing costs, improving efficiency, and enhancing patient care. By integrating these technologies, the venture may set a precedent for future partnerships between tech companies and healthcare providers. However, the success of the initiative will depend on execution, regulatory approvals, and market adoption.

For more details, the full press release is available at https://ibn.fm/yIVh9. Information about Datavault AI can be found at www.dvlt.ai. Forward-looking statements in this release are subject to risks and uncertainties, as detailed in the company's SEC filings.